A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality
The current study combines a molecular genetic perspective, self report and brain imaging to the study of human sexuality in control subjects and individuals from a sexual disorder clinic. The investigators hypothesize that the variability in components of the brain dopaminergic system expressed in the mesolimbic reward system can explain variability in human sexuality, especially in desire and pleasure associated with sex.
Hypoactive Sexual Desire Disorder
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality|
- Brain Imaging data of DRD2 receptor occupancy during watching a sex videotape and neutral videotape [ Time Frame: 2 Brain imaging sessions a week apart ] [ Designated as safety issue: Yes ]
- Questionnaire ratings of human sexuality, pleasure, and anticipatory reward [ Time Frame: Taken during brain scans ] [ Designated as safety issue: No ]
|Study Start Date:||April 2011|
|Estimated Study Completion Date:||October 2011|
|Estimated Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
We intend to combine molecular genetics of the dopamine receptors (D2, D3 D4 and D5) and brain imaging using 11 C Raclopride in Positron Emission Tomography (PET). 11 C Raclopride is a ligand which binds to the dopamine receptor D2 and can measure dopamine release during pleasure or anticipatory reward associated with sex. The current proposal will measure changes in DRD2 receptor occupancy using 11 C Raclopride following explicit visual sexual desire cues in healthy control subjects and individuals who suffer from sexual dysfunction. This is in order to determine how individual genotypes modulate dopamine release in vivo in the human brain.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00569413
|Principal Investigator:||Aviv M Weinstein, Ph.D||Hadasah Medical Organization, Jerusalem Israel|